Based on the provided financial report articles, I generated the title for the article: "Quarterly Report for the Three Months Ended March 31, 2026 (Form 10-Q)" Please note that the title may not be exact, as the provided text appears to be a financial report in XML format, and the title may not be explicitly stated.
The financial report presents the financial statements of the company for the first quarter of 2026. The company reported a net loss of $X million, with total revenue of $Y million and total expenses of $Z million. The company’s cash and cash equivalents decreased by $X million to $Y million, and its accounts payable and accrued expenses increased by $X million to $Y million. The company’s stockholders’ equity decreased by $X million to $Y million. The company’s convertible preferred stock and warrants outstanding as of March 31, 2026, were $X million and $Y million, respectively. The company’s employee stock options outstanding as of March 31, 2026, were $X million. The company’s restricted stock outstanding as of March 31, 2026, was $X million. The company’s healthcare patient service revenue was $X million, and its histology service fees revenue was $X million. The company’s medical director fees revenue was $X million.
Company Overview
The company develops noninvasive diagnostics to detect early-stage lung cancer and other lung diseases using flow cytometry and automated analysis developed by machine learning. Their main diagnostic test, CyPath® Lung, addresses the need for noninvasive detection of early-stage lung cancer, which is the leading cause of cancer-related deaths worldwide. CyPath® Lung is offered for sale to physicians through the company’s wholly owned subsidiary, Precision Pathology Services (PPLS). The company also conducts research through its subsidiary OncoSelect® Therapeutics, LLC, which has led to discoveries and advancement of novel cancer therapeutic approaches.
Business
The company’s core business is the development and commercialization of its CyPath® Lung diagnostic test. CyPath® Lung analyzes cell populations, including cancer and cancer-related cells, that are indicative of lung cancer. The test enables physicians to more confidently identify patients who will likely benefit from timely intervention and those who are likely without lung cancer and should continue routine screening. The company believes CyPath® Lung has the potential to increase overall diagnostic accuracy of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.
The company also conducts research through its subsidiary OncoSelect® Therapeutics, LLC, which has led to discoveries and advancement of novel cancer therapeutic approaches that specifically and selectively target cancer cells. The company plans to seek strategic partners to develop these therapeutic discoveries in the future.
Current Year Financial Highlights
Key financial results for the three months ended March 31, 2026 include:
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| CyPath® Lung Unit Sales | 146% growth | - | - |
| CyPath® Lung Testing Revenue | $361,000 | $169,000 | 114% increase |
| Consolidated Revenue | $1.4 million | $1.9 million | 36% decrease |
Recent Developments
- In April 2026, the CyPath® Lung test was featured at the “Advances in Early Lung Cancer Detection” symposium at the Cleveland Clinic.
- In March 2026, the company enrolled its first patient in a clinical trial for the CyPath® Lung test, supported by the John P. Murtha Cancer Center Research Program.
- In March 2026, the company announced additional patient case studies where the CyPath® Lung test result of “Unlikely Malignancy” relieved patient anxiety and supported the physician’s decision to continue routine screening.
Financial
The company has funded its operations primarily through private and public sales of equity, issuance of debt, and the exercise of warrants and stock options. As of March 31, 2026, the company had $3.0 million in cash and cash equivalents, which management expects will support operations through June 2026.
The company has incurred significant losses and negative cash flows from operations since inception and expects to continue to do so for the foreseeable future. Based on the company’s current expected level of operating expenditures and cash on hand, management concludes that there is substantial doubt about the company’s ability to continue as a going concern for at least the next 12 months.
The company anticipates raising additional cash needed through private or public sales of equity or debt, collaborative arrangements, or a combination thereof to continue funding its operations and product development.
Results of Operations
For the three months ended March 31, 2026, the company reported a net loss of $3.6 million, compared to a net loss of $2.7 million for the same period in 2025. The increase in net loss was primarily driven by:
- A 36% decrease in consolidated revenue to $1.4 million, due to discontinuing certain unprofitable pathology services, partially offset by a 114% increase in CyPath® Lung testing revenue.
- A 32% increase in selling, general, and administrative expenses to $3.2 million, primarily due to increased employee compensation and support services for the growth of CyPath® Lung sales.
- A 141% increase in clinical development expenses to $334,000, due to the start of the company’s pivotal clinical trial.
Liquidity, Capital Resources, and Going Concern
The company has incurred losses since inception and expects to continue to incur substantial additional losses in future periods. As of March 31, 2026, the company had an accumulated deficit of $72.2 million.
Management concludes that there is substantial doubt about the company’s ability to continue as a going concern for at least the next 12 months, based on its current expected level of operating expenditures, revenue, and cash on hand. The company will need to raise additional capital through financing transactions or collaborative arrangements to support its future operations and product development.
Summary
The company is focused on the development and commercialization of its CyPath® Lung diagnostic test for early-stage lung cancer detection. While the company has seen strong growth in CyPath® Lung sales, it continues to face financial challenges, including significant operating losses and doubts about its ability to continue as a going concern. The company is actively seeking additional funding sources to support its operations and product development efforts.
